• Search
  • Advanced Search
Clin Mol Hepatol > Volume 31(2); 2025 > Article
Yim, Lee, Baek, Sohn, Jeong, Kang, Park, Park, Lee, Kaseb, Park, Leem, Curran, Kim, and Lee: Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Erratum

Clin Mol Hepatol. 2025; 31(2): 669-670.

Published online: February 27, 2025

DOI: https://doi.org/10.3350/cmh.2024.0333e

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim1, *, Sung Hwan Lee2, *, Seung-Woo Baek3, Bohwa Sohn4, Yun Seong Jeong4, Sang-Hee Kang5, Kena Park6, 7, Hyewon Park4, Sunyoung S. Lee8, Ahmed O. Kaseb8, Young Nyun Park9, Sun-Hee Leem10, 11, Michael A. Curran12, Ji Hoon Kim1, Ju-Seog Lee4

Corresponding author : Ju-Seog Lee Department of Systems Biology, Unit 1058, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
Tel: +1-713-834-6154, Fax: +1-713-563-4235, E-mail: jlee@mdanderson.org

*These authors equally contributed to the writing of this manuscript.

Copyright © 2025 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused.
The original article has been corrected as of 27th February 2025.
Before correction
Figure 4B.
cmh-2024-0333ei1.jpg
After correction
Figure 4B.
cmh-2024-0333ei2.jpg
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 577 View
  • 36 Download
ORCID iDs

Ju-Seog Lee
https://orcid.org/0000-0002-5666-9753

Related articles

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”2025 January;31(1)

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”2025 January;31(1)

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”2025 January;31(1)

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”2025 January;31(1)

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma2025 January;31(1)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 672
TOTAL : 2631671
Close layer